Sirtex Medical Inc. is an American company with an approved cancer treatment supplied globally. Sirtex's main commercialized product is a targeted radioactive treatment for liver cancer called SIR-Spheres® Y-90 resin microspheres.
Over 92,000 doses of SIR-Spheres Y-90 resin microspheres have been supplied to treat liver cancer patients at over 1,230 medical centers in over 40 countries.
This product has PMA approval from the U.S. Food & Drug Administration (FDA), the European Union (CE Mark) and Australia's Therapeutic Goods Administration (TGA).
Sirtex has manufacturing capabilities in the U.S., Singapore and Germany.